Tumor Necrosis Factor Blocker [EPC]

806700 reported adverse events

Drugs of this class: INFLIXIMAB GOLIMUMAB CERTOLIZUMAB PEGOL ETANERCEPT INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 94496
1 INJECTION SITE PAIN 57665
2 ARTHRALGIA 53101
3 PAIN 48175
4 RHEUMATOID ARTHRITIS 47201
5 OFF LABEL USE 46405
6 INJECTION SITE ERYTHEMA 41500
7 FATIGUE 36004
8 CONDITION AGGRAVATED 29736
9 HEADACHE 29301
See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 287 0.9762
1 INJECTION SITE RECALL REACTION 482 0.9737
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 3174 0.9418
3 SWOLLEN JOINT COUNT INCREASED 680 0.9067
4 RHEUMATOID FACTOR POSITIVE 2705 0.8808
5 RED BLOOD CELL SEDIMENTATION RATE ABNORMAL 1639 0.8384
6 RHEUMATIC FEVER 872 0.8119
7 PEMPHIGUS 5646 0.8016
8 C-REACTIVE PROTEIN ABNORMAL 2720 0.7774
9 HAND DEFORMITY 5774 0.7270
See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]